Mental Health and Substance Use Disorder (MHSUD) treatment issues have posed a growing challenge across the health care landscape in recent years. The COVID-19 pandemic of 2020 has further exacerbated the challenges facing MHSUD patients and their care providers.
The evidence is stark and alarming: In the United States, the suicide rate is the highest on record and the opioid crisis continues to rage in many parts of the country, with heroin usage up 147% since 2007.
MHSUD diagnoses act as a multiplier for other diagnoses and can increase treatment time, intensity and cost. However, as we overcome the stigma of MHSUD diagnoses, the lack of access to care has become a challenge for many patients, leading to issues at the both societal and workforce level, including absenteeism and lost productivity.
The move from our current fragmented health care delivery system to a reformed system requires five inter-related activities; Measurement-Based Care (MBC) is one of them, along with improved access, MHSUD parity compliance, tele-behavioral health, and collaborative care models.
MBC is a key tenet for The Path Forward for Mental Health and Substance Use in promoting earlier diagnosis and more effective care resulting in 20-60% better clinical outcomes. URAC has taken a leadership position with its new MBC Designation that helps to promote improved MHSUD diagnosis and care in both primary and specialty care.
Dr. Shawn Griffin, URAC’s President and CEO, will discuss URAC’s efforts at a webinar, “New URAC Measurement-Based Care Designation to Improve Behavioral Health Outcomes” on August 26. The webinar will be hosted by Mike Thompson, President and CEO of The National Alliance of Healthcare Purchaser Coalitions.
Griffin and Thompson will discuss MBC’s role in the future of health care and URAC’s role in supporting better outcomes for patients, payers, and purchasers within the context of the broader Path Forward agenda.
For more information, register here